UPM Pharmaceuticals buys Pfizer plant in Tennessee
Provides large-scale manufacturing and packaging of tablets and capsules
UPM Pharmaceuticals, a Baltimore, MD, US-based drug development and contract manufacturer, has bought a 500,000ft2 commercial manufacturing facility in Bristol, TN from Pfizer, for an undisclosed sum.
UPM said the facility provides large-scale commercial capabilities for manufacturing and packaging solid oral dosage tablets and capsules, as well as semi-solid manufacturing of creams and ointments.
In addition, the plant provides for technology transfer support, pilot plant scale-up capabilities, analytical and microbial testing, as well as dedicated suites for potent compounds.
As part of the deal, UPM will continue to manufacture Pfizer's products at the plant for two years.
UPM's President, James Gregory, said the new facility would enable the company ‘to offer clients a seamless transition from early stage formulation development to commercialisation along with all associated comprehensive lab support’.
He said the plant would also provide ‘a dramatic growth opportunity’ for UPM, giving the capability to produce 3.5 billion tablets and 680 million capsules annually.
The Pfizer site was previously home to King Pharmaceuticals before being acquired in 2010 for US$3.6bn. King Pharmaceuticals was founded by UPM's Chairman and CEO John Gregory.
